Originally published as JCO Early Release 10.1200/JCO.2009.22.3875 on August 24 2009

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Zangari, M. Articles by Tricot, G. J. PubMed PubMed Citation Articles by Zangari, M. Articles by Tricot, G. J. Social Bookmarking                            What's this?

Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents

From the University of Utah, Division of Hematology, Blood/Marrow Transplant and Myeloma Program, Salt Lake City, UT; Nevada Cancer Institute, Laboratory Medicine, Las Vegas, NV; Esoterix, Aurora, CO; and St Bortolo Hospital, Vicenza, Italy.

Corresponding author: Maurizio Zangari, MD, 30 North 1900 East, SOM Rm 5C402, Salt Lake City, UT 84132; e-mail: maurizio.zangari{at}hsc.utah.edu.

Tumor-associated neoangiogenesis has recently become a suitable target for antineoplastic drug development. In this overview, we discuss specific drug-associated hemostatic complications, the already known pathogenetic mechanisms involved, and the effect of varying antithrombotic strategies. Multiple agents with angiogenic inhibitory capacity (thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib, and sirolimus) have obtained US Food and Drug Administration approval, and many others have entered clinical trials. Arterial and venous thromboembolism and hemorrhage have emerged as significant toxicities associated with the use of angiogenesis inhibitors. We present a detailed analysis of the literature on thrombotic complication of antiangiogenic drugs. Close attention to hemostatic complications during antiangiogenic treatment is warranted. Further studies are required to better understand the pathophysiologic mechanisms involved and to define a safe prophylactic strategy.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. H. Lyman and A. A. Khorana Cancer, Clots and Consensus: New Understanding of an Old Problem J. Clin. Oncol., October 10, 2009; 27(29): 4821 - 4826. [Full Text] [PDF]

				P. Rana and M. N. Levine Prevention of Thrombosis in Ambulatory Patients With Cancer J. Clin. Oncol., October 10, 2009; 27(29): 4885 - 4888. [Abstract] [Full Text] [PDF]